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httpcense.Abstract Introduction: Introduction:The complications of injection sclerotherapy can be divided
broadly into two categories, those occurring at the site of injection and those resulting from sys-
temic dissemination of the sclerosant through the paraesophageal and azygos veins; this has been
shown radiologically. Endoscopic variceal ligation (EVL) was developed as an alternative endo-
scopic method of treating esophageal varices with the anticipation that EVL would be as effective
as EIS, but with fewer complications. We aimed in this study to assess the safety of both procedures
for the lung.
Patients and methods: We studied 28 patients with chronic liver disease and portal hypertension,
14 patients underwent injection sclerotherapy of ethanolamine oleate and the other 14 underwent
band ligation. All patients underwent spirometery and ABG pre, 2 days and 3 weeks from the pro-
cedures.
Results: Two days after the procedures the PEF and FEF 50 decreased highly signiﬁcantly in
EST patients when compared to EBL patients (P value less than 0.001), and FEV1, FVC,
FEF25, FEF75, Pao2 and o2 sat decreased signiﬁcantly in the same group by a P value of lessligation; EST, esophageal
forced vital capacity; FEV1,
, peak expiratory ﬂow; In,
expiratory ﬂow; ABG, arterial
Pao2, arterial oxygen tension;
01063840128.
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770 N.A. Rezk, N.A. El-Malekythan 0.05. After 3 weeks from the procedures the VCin, VCex, FEV1, FVC and FEF25
decreased highly signiﬁcantly in the EST group (P value was less than 0.001), and the FEF
50, PEF, PACO2, PAO2 and O2 SAT decreased signiﬁcantly in the same group. And there
was a signiﬁcant decrease of ﬂow, FEV1 and FVC 2 days after the EST group with a highly
signiﬁcant decrease of PAO2 and O2SAT when compared to the same patients before the
EST and we found a highly signiﬁcant decrease of VC, FEV1, FVC, PAO2 and O2 SAT pre
and 3 weeks from EST.
Conclusions: From this study we conclude that the band ligation is safe for the lung and may
be an option to eradicate esophageal varices in chronic lung disease patients.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
Bleeding from esophageal varices is the most serious compli-
cation of portal hypertension and is the leading cause of cir-
rhosis-related deaths [1]. Endoscopic injection sclerotherapy
became an established method of controlling variceal bleed-
ing worldwide following the initial prospective studies [2],
Endoscopic variceal ligation (EVL) was developed as an
alternative endoscopic method of treating esophageal varices
with the anticipation that EVL would be as effective as EIS,
but with fewer complications [3]. There is no consensus
regarding the deﬁnition or classiﬁcation of the complications
that occur after the endoscopic treatment of esophageal and
gastric varices, and consequently the incidence varies widely
in reported studies [4]. Much of the published data are ﬂawed
because the reporting process is often biased with subjective
and retrospective information, and complication rates are
generally operator dependent [5]. The complications can be
divided broadly into two categories, those occurring at the
site of injection and those resulting from systemic dissemina-
tion of the sclerosant through the paraesophageal and azygos
veins; this has been shown radiologically [6]. Abnormalities of
organ function have been described including abnormal chest
radiology and, more rarely, respiratory failure. Injection of
varicose veins in the legs has also resulted in acute renal fail-
ure [7]. Esophageal injection sclerotherapy is associated with
a restrictive defect in respiratory function one day after the
injection caused, possibly, by sclerosant embolisation to the
lung [8].Patients and methods
We studied 28 patients males with chronic liver disease and
portal hypertension, 14 patients underwent injection sclero-
therapy of ethanolamine oleate and another 14 underwent
band ligation.
All patients underwent all of the following:
(1) Complete history and clinical examination.
(2) Routine investigations, CBC, LFT, RFT, coagulation
proﬁle.
(3) Chest X ray before the study, 2 days after the
procedure and 3 weeks after the procedure.
(4) Spirometery before the study, 2 days after the
procedure and 3 weeks after the procedure.(5) Arterial blood gas before the study, 2 days after the
procedure and 3 weeks after the procedure.
Exclusion criteria:
(1) Any patients with chest complaint before or during
the study period.
(2) Chest X ray abnormalities before or during the study
period. Except blunted costo-phrenic angle.
(3) Uncooperative patients.
(4) Patients with chronic lung diseases.
(5) Current smokers.
Technique of sclerotherapy [9]
Under conscious sedation we introduce the upper GIT endos-
copy through the mouth of patients. We inject Ethanol no
more than a 4-mL volume as recommended in an intravariceal
fashion. In the intravariceal technique, sclerosant is injected di-
rectly into the varix.
In the paravariceal technique, 1 to 2 mL of the sclerosant is
injected in the submucosa adjacent to the visible varices.
The ﬁrst injection starts at the GE junction and can be re-
peated circumferentially and proximally up to 10 cm, up to 20
to 50 times during a single or several sessions.
Commonly used needles for injection generally include
23-gauge to 25-gauge needles that are no longer than 5 mm
from the catheter tip. Intervals between sclerotherapy
sessions to obliterate varices vary. Commonly reported fre-
quencies range from 1 to 3 weeks, for an average of 3 to 6
sessions.
Spirometery technique [10]
We avoid conditions where suboptimal lung function results
are likely:
(1) Chest or abdominal pain of any cause.
(2) Oral or facial pain exacerbated by a mouthpiece.
(3) Stress incontinence.
(4) Dementia or confusional state.
Subject preparation
Activities that should preferably be avoided prior to lung func-
tion testing:
Table 1 Demographic data and biochemical investigation of
the two groups of study.
EST EBL P value
Age 44.64 ± 12.68 47.79 ± 3.26 0.383
WBCs 5.41 ± 2.47 4.21 ± 0.75 0.104
RBCs 3.64 ± 0.56 3.77 ± 0.80 0.609
Hb 10.00 ± 1.11 11.31 ± 1.99 0.044
Platelet 110.00 ± 14.86 103.07 ± 48.92 0.619
Creatinine 1.10 ± 0.34 1.41 ± 0.60 0.113
INR 1.36 ± 0.37 1.58 ± 0.24 0.071
Alb 3.44 ± 0.49 3.36 ± 0.44 0.659
SGPT 43.86 ± 15.00 44.00 ± 24.47 0.985
SGOT 49.57 ± 17.93 56.93 ± 20.72 0.324
K 3.23 ± 0.47 3.56 ± 0.69 0.163
There is no signiﬁcant difference between the two groups before the
procedures in regard to demographic data and biochemical
investigations.
Table 2 Comparison between two groups with regard to the
spirometric parameter and ABG results before the procedure.
Before procedure EST (n= 14) EBL (n= 14) P value
Vcin 71.74 ± 12.04 73.66 ± 18.52 0.747
Vcex 68.93 ± 10.75 70.89 ± 10.67 0.633
FEV1 83.71 ± 5.72 82.55 ± 13.80 0.774
FVC 70.96 ± 8.52 72.49 ± 8.50 0.639
FEF 25 75.17 ± 28.36 79.81 ± 17.38 0.607
FEF 50 78.97 ± 24.28 101.94 ± 21.44 0.013
FEF 75 106.44 ± 38.77 85.46 ± 56.93 0.266
PEF 88.19 ± 61.82 69.16 ± 16.72 0.277
PCO2 31.59 ± 3.90 29.58 ± 2.85 0.131
PO2 98.68 ± 22.92 85.84 ± 9.59 0.069
O2 sat 96.73 ± 1.88 96.56 ± 1.33 0.791
There is no signiﬁcant difference between the two groups before the
procedure in all spirometric parameters and ABG results, except
that FEF 50 was better for the EBL group, P value was 0.013 and
pao2 was better for the EST group whose P value was 0.06.
Pulmonary function changes after ethanolamine 771(1) Smoking within at least 1 h of testing.
(2) Consuming alcohol within 4 h of testing.
(3) Performing vigorous exercise within 30 min of testing.
(4) Wearing clothing that substantially restricts full chest
and abdominal expansion.
(5) Eating a large meal within 2 h of testing.
Recommendation: vital capacity (VC) [11]
VC= The maximal volume of air exhaled from the point of
maximal inhalation or the maximal volume of air inhaled from
a point of maximal exhalation can be measured with a slow
exhalation or inhalation, respectively. This was previously
called the ‘‘slow’’ vital capacity and has been better described
as the ‘‘relaxed vital capacity’’ [13]. The VC is expressed in
liters (BTPS).
Recommendation: forced vital capacity (FVC) [11]
FVC=Maximal volume of air exhaled with maximally forced
effort from a position of maximal inspiration, i.e., vital
capacity performed with a maximally forced expiratory effort,
expressed in liters (BPS).
Recommendation: timed forced expiratory volume (FEV)
FEV= The volume of air exhaled in the speciﬁed time during
the performance of the FVC, e.g., FEV, for the volume of air
exhaled during the ﬁrst second of FVC, expressed in liters
(BTPS).
Technique of ABG[12]
Accurate results for ABGs depend on collecting, handling,
and analyzing the specimen properly. Clinically important
errors may occur at any of these steps, but ABG measure-
ments are particularly vulnerable to pre analytic errors.
The most common problems include non arterial samples,
air bubbles in the sample, either inadequate or excessive
anticoagulant in the sample, and delayed analysis of an
un-cooled sample.
A proper blood sample for ABG analysis consists of a 2 to
3 ml arterial specimen collected anaerobically from a periphe-
ral artery in a 3- or 5-ml plastic or glass, airtight syringe ﬁtted
with a small-bore needle. Any air bubbles inadvertently intro-
duced during sampling must be promptly evacuated. Room air
has a Po2, of approximately 150 mmHg (sea level) and a Pco2
of essentially zero. Thus, air bubbles that mix and equilibrate
with arterial blood will shift the Pao2 toward 150 mmHg and
will lower the Paco2.
Heparin must be added to the syringe as an anticoagulant.
Because the pH of heparin is near 7.0, and the Po2 and Pco2 of
the heparin solution are near room air values, excess heparin
can alter all three ABG measurements. Very little heparin is
actually needed in the sample to prevent clotting; 0.05 to
0.10 ml of a dilute solution (1000 units/ml) will anticoagulate
1 ml of blood without affecting its pH, Pco2, or Po2. After
ﬂushing the syringe with heparin, a sufﬁcient amount usually
remains in the dead space of the syringe and needle for antico-
agulation without distortion of the ABG determination.
After collection, the specimen should be analyzed expedi-
tiously. If a delay of more than 10 min is anticipated, thespecimen must be immersed in an ice bath. Leukocytes and
platelets continue to consume oxygen in the sample after it is
drawn and can cause a signiﬁcant fall in Pao2 over time at
room temperature, especially in the setting of leukocytosis or
thrombocytosis. Cooling will prevent any clinically important
effect for at least 1 h by decreasing the metabolic activity of
these cells.
ABGs are now routinely measured with an automated
analyzer.
Data was analyzed using SPSS (Statistical Package for So-
cial Sciences) version 15. Data was presented as mean ± SD.
Paired t-test was used for comparison within groups. Student’s
t-test was used to compare between two groups. P< 0.05 was
considered to be statistically signiﬁcant.
Results
The results are shown in (Tables 1–8)
Table 3 Comparison between the two groups with regard to the spirometric parameter and ABG results 2 days post procedure.
2 days after the procedure EST (n= 14) EBL (n= 14) P value
Vcin 52.32 ± 9.33 65.24 ± 13.49 0.001
Vcex 55.91 ± 12.14 64.61 ± 12.20 0.001
FEV1 66.04 ± 10.97 84.29 ± 2.42 0.001
FVC 55.59 ± 12.60 73.49 ± 7.55 0.001
FEF 25 73.36 ± 16.69 79.85 ± 27.37 0.213
FEF 50 88.56 ± 17.02 98.67 ± 21.06 0.041
FEF 75 107.61 ± 33.58 108.56 ± 28.74 0.723
PEF 62.69 ± 20.00 80.15 ± 21.00 <0.001
pa CO2 33.71 ± 2.23 30.21 ± 3.17 0.104
PaO2 77.29 ± 10.70 85.43 ± 9.73 0.045
O2 SAT 94.43 ± 3.01 96.29 ± 0.83 0.042
Two days after the procedure there was a highly signiﬁcant decrease of VC, FVC, FEV1, and PEF in EST patients (P value .001) and a
signiﬁcant decrease of FEF 50, Pao2 and o2sat in the same group when compared to EBL patients.
Table 4 Comparison between the two groups with regard to the spirometric parameter and ABG results 3 weeks post procedure.
3 weeks post procedure EST (n= 14) EBL (n= 14) P value
Vcin 60.89 ± 12.87 74.88 ± 11.60 0.045
Vcex 65.91 ± 12.14 76.07 ± 8.99 0.042
FEV1 76.04 ± 10.97 89.41 ± 12.07 0.032
FVC 65.59 ± 12.60 77.13 ± 10.00 0.050
FEF 25 78.36 ± 16.69 87.47 ± 15.75 0.050
FEF 50 88.56 ± 17.02 101.27 ± 11.85 0.031
FEF 75 107.61 ± 33.58 112.69 ± 26.90 0.662
PEF 62.69 ± 20.00 84.21 ± 21.02 0.010
Pa CO2 33.71 ± 2.23 30.29 ± 3.31 0.004
PaO2 85.18 ± 10.70 85.71 ± 8.71 0.233
O2 SAT 95.73 ± 3.21 95.79 ± 0.89 0.423
After 3 weeks from procedure the VCin, VCex, FEV1, FVC, PEF, FEF25, paco2 and FEF25 were signiﬁcantly decreased in EST patients (P
value was 0.050 or less), when compared with the EBL group.
Table 5 Spirometric parameter and ABG results in patients
with injection sclerotherapy before and 2 days after the
procedure.
EST Before EST 2 days P value
Vcin 71.74 ± 12.04 52.32 ± 9.33 <0.001
Vcex 68.93 ± 10.75 55.91 ± 12.14 <0.001
FEV1 83.71 ± 5.72 66.04 ± 10.97 <0.001
FVC 70.96 ± 8.52 55.59 ± 12.60 <0.001
FEF 25 75.17 ± 28.36 73.36 ± 16.69 0.415
FEF 50 78.97 ± 24.28 88.56 ± 17.02 0.024
FEF 75 106.44 ± 38.77 107.61 ± 33.58 0.528
PEF 88.19 ± 61.82 62.69 ± 20.00 0.042
PCO2 31.59 ± 3.90 33.71 ± 2.23 0.684
PO2 98.68 ± 22.92 77.29 ± 10.70 <0.001
O2 sat 96.73 ± 1.88 94.43 ± 3.01 <0.001
There was a highly signiﬁcant decrease of VC, FVC, FEV1, pao2
and o2 sat and a signiﬁcant decrease of FEF 50 and PEF pre and
2 days from EST.
Table 6 Spirometric parameter and ABG results of patients
with injection sclerotherapy before and 3 weeks after the
procedure.
EST Before EST 3 weeks P value
Vcin 71.74 ± 12.04 60.89 ± 12.87 0.0468
Vcex 68.93 ± 10.75 65.91 ± 12.14 0.527
FEV1 83.71 ± 5.72 76.04 ± 10.97 0.0489
FVC 70.96 ± 8.52 65.59 ± 12.60 0.0365
FEF 25 75.17 ± 28.36 78.36 ± 16.69 0.842
FEF 50 78.97 ± 24.28 88.56 ± 17.02 0.197
FEF 75 106.44 ± 38.77 107.61 ± 33.58 0.927
PEF 88.19 ± 61.82 62.69 ± 20.00 0.218
PCO2 31.59 ± 3.90 33.71 ± 2.23 0.114
PO2 98.68 ± 22.92 85.18 ± 10.70 0.0482
O2 sat 96.73 ± 1.88 95.73 ± 3.21 0.0497
There was a signiﬁcant decrease of Vcin, FEV1, FVC, PAO2 and
O2 SAT before and 3 weeks from EST.
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Endoscopic injection sclerotherapy became an established
method of controlling variceal bleeding worldwide following
the initial prospective studies [2], Endoscopic variceal ligation(EVL) was developed as an alternative endoscopic method of
treating esophageal varices with the anticipation that EVL
would be as effective as EIS, but with fewer complications
[3]. Esophageal injection sclerotherapy is associated with a
restrictive defect in respiratory function one day after the injec-
tion caused, possibly, by sclerosant embolisation to the lung
Table 7 Spirometric parameter and ABG to patients with a
band ligation before and 2 days after the procedure.
EBL before EBL 2 day P value
Vcin 73.66 ± 18.52 65.24 ± 13.49 0.148
Vcex 70.89 ± 10.67 64.61 ± 12.20 0.133
FEV1 82.55 ± 13.80 84.29 ± 2.42 0.973
FVC 72.49 ± 8.50 73.49 ± 7.55 0.953
FEF 25 79.81 ± 17.38 79.85 ± 27.37 0.994
FEF 50 101.94 ± 21.44 98.67 ± 21.06 0.530
FEF 75 85.46 ± 56.93 108.56 ± 28.74 0.151
PEF 69.16 ± 16.72 80.15 ± 21.00 0.079
PCO2 29.58 ± 2.85 30.21 ± 3.17 0.612
PO2 85.84 ± 9.59 85.43 ± 9.73 0.125
O2 SAT 96.56 ± 1.33 96.29 ± 0.83 0.345
There are no signiﬁcance differences before and 2 days from EBL.
Table 8 Spirometric parameter and ABG results in patients
with band ligation before and 3 weeks after the procedure.
EBL before EBL 3 weeks P value
Vcin 73.66 ± 18.52 74.88 ± 11.60 0.814
Vcex 70.89 ± 10.67 76.07 ± 8.99 0.149
FEV1 82.55 ± 13.80 89.41 ± 12.07 0.118
FVC 72.49 ± 8.50 77.13 ± 10.00 0.101
FEF 25 79.81 ± 17.38 87.47 ± 15.75 0.111
FEF 50 101.94 ± 21.44 101.27 ± 11.85 0.926
FEF 75 85.46 ± 56.93 112.69 ± 26.90 0.228
PEF 69.16 ± 16.72 84.21 ± 21.02 0.098
PCO2 29.58 ± 2.85 30.29 ± 3.31 0.574
PO2 85.84 ± 9.59 85.71 ± 8.71 0.860
O2 SAT 95.56 ± 1.33 95.79 ± 0.89 0.114
There are non signiﬁcance differences before and 3 weeks from
EBL.
Pulmonary function changes after ethanolamine 773[8]. In this study we compared two groups which were sched-
uled to have elective sclerotherapy or band ligation of their
esophageal varices for the ﬁrst time under local anesthesia.
In a band ligation group and injection sclerotherapy group
in regard to pulmonary function, we aimed to see the safety
of each maneuver, rapidly after and 3 weeks from the proce-
dure. We found a highly signiﬁcant decrease in VC, FVC,
FEV1 and PEF, and a signiﬁcant decrease of FEF50, pao2,
and o2sat 2 days after the injection sclerotherapy when com-
pared with EBL and also a highly signiﬁcant decrease of VC,
FVC, FEV1, pao2 and o2 sat in the EST group when com-
pared before and 2 days after the procedure, this indicates that
a restrictive ventilatory defect occurred after injection sclero-
therapy and this ﬁnding agreed with Samuels et al. (1994) [8]
who found a decrease of lung function one day after injection
sclerotherapy and explained this by embolism of a sclerosant
agent to pulmonary vessels and also with Papiamonisa et al.
(2012) [13] who found a case report with acute PE after injec-
tion sclerotherapy with N-butyl-cyanoacrylate. After 3 weeks
from EST there were signiﬁcance decrease of VC, FVC,
FEV1, PEF, FEF25 and paco2 when compared with the
EBL group and also a signiﬁcant decrease of VC, FVC,
FEV1, pao2 and o2 sat in the same group when comparedbefore and 3 weeks after the procedure and this means partial
improvement of EST patients after 3 weeks from EST but
there was no complete resolution of this ventilatory defect
and up till now to our knowledge no body examined
pulmonary function after this period from EST or EBL, this
may be explained by an incomplete resolution of embolism
of a sclerosant agent to pulmonary vasculature or interstitial
pneumonites from the sclerosant agent and we think that the
safety of these agents to the lung must be reviewed. At the
same time there was no effect of band ligation in the studied
group 2 days or 3 weeks from the procedure and this may ex-
plained by no chemical substance injection intra or around the
varices.
From this study we conclude that the band ligation is safe
to the lung and may be an option to eradicate esophageal var-
ices in chronic lung disease patients.
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